Overview

At Protheragen, our solution to anti-obesity therapeutics extends to targeting a variety of metabolic regulators, which are crucial in modulating energy balance, fat storage, and metabolism. These regulators influence key pathways that significantly impact weight management and metabolic health. By modulating these pathways, we aim to provide advanced therapeutic solutions that address the root causes of obesity, rather than simply managing its symptoms.

Transforming Metabolism, Redefining Obesity Treatment

Our solutions offer a comprehensive approach that incorporates anti-obesity therapy development, and preclinical studies to ensure the effectiveness and safety of the treatments. This focuses on targeting metabolic regulators like endocannabinoids, sirtuins, and myokines to design highly effective therapeutic candidates that modulate pathways essential for energy balance and fat metabolism. These solutions are further validated through preclinical studies of anti-obesity therapeutics, where we utilize advanced obesity models, pharmacokinetics, pharmacodynamics, and bioanalysis to confirm their efficacy in controlled settings.

To ensure safety, we also offer Safety Pharmacology Studies, assessing potential effects on physiological systems such as cardiovascular, respiratory, and central nervous systems, ensuring the therapies meet the highest safety standards. Our extensive expertise is encapsulated in our services, offering fully customized solutions from target discovery to preclinical development and drug optimization.

Applications

• Inhibiting CB1 to reduce appetite and prevent fat accumulation.
• Enhancing SIRT1 activity promotes fat oxidation, increases energy expenditure, and improves insulin sensitivity.
• Leveraging myokines like irisin to boost fat burning, promote lean muscle mass, and improve metabolic health, simulating the effects of exercise through therapeutic compounds.

Advantages

• By focusing on specific metabolic pathways, our solutions offer a more precise and effective method for developing drugs for obesity compared to traditional weight-loss drugs.
• Targeting the underlying metabolic regulators helps facilitate long-term weight loss by restoring the body's natural ability to regulate fat storage and energy balance.
• Therapies based on metabolic regulators often exhibit fewer side effects, particularly compared to centrally acting weight-loss medications, making them safer for long-term use.
• Beyond weight loss, these therapies improve broader metabolic markers such as insulin sensitivity, glucose regulation, and lipid profiles, addressing obesity-related diseases like Type 2 diabetes and cardiovascular disease.

Our Services

Targeting metabolic regulators is a cornerstone of anti-obesity therapeutic development. We offer a range of services that explore key metabolic pathways and regulators. You can also click the "our service" button above to enter our service section and learn more about our services.

Frequently Asked Questions

What are metabolic regulators, and why are they important for developing anti-obesity therapeutics?

Metabolic regulators are molecules and proteins that play a critical role in controlling the body's metabolism, energy balance, fat storage, and appetite. By targeting these regulators, we directly influence the biological pathways responsible for obesity, making treatments more effective in promoting sustainable weight loss and improving metabolic health.

How does targeting endocannabinoids help in treating obesity?

The endocannabinoid system, specifically through CB1, plays a significant role in regulating appetite and fat accumulation. By developing compounds that inhibit CB1, we reduce excessive food intake and prevent fat storage, offering a targeted approach to managing obesity without affecting central nervous system functions.

Publication

Discover the innovative potential of targeting metabolic regulators for developing anti-obesity therapeutics at Protheragen, please feel free to contact us for more information and to explore custom solutions.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Targeting Enzymes and Proteins for Developing Anti-Obesity Therapeutics
• Targeting Hormones and Peptides for Developing Anti-Obesity Therapeutics
• Targeting Receptors for Developing Anti-Obesity Therapeutics
• Targeting Signaling Molecules for Developing Anti-Obesity Therapeutics